#124193
Re: Farmas USA
NVAX
Parece q fue buena entrada la de ayer a 95,50
Solo media carga
Novavax provides additional data on COVID-19 vaccine candidate
- Novavax (NASDAQ:NVAX) announces the publication of Phase 1 data from its Phase 1/2 trial of COVID‑19 vaccine candidate NVX‑CoV2373, adjuvanted with Matrix‑M, in 131 healthy adults 18-59 years of age in The New England Journal of Medicine.
- The publication offers further detail on the previously announced NVX‑CoV2373 results with and without the Matrix-M adjuvant.
- After randomization, 83 participants were assigned to receive the vaccine with adjuvant and 25 without adjuvant, and 23 participants were assigned to receive placebo.
- The addition of adjuvant resulted in enhanced immune responses, was antigen dose–sparing, and induced a T helper 1 (Th1) response. The two-dose 5-μg adjuvanted regimen induced geometric mean anti-spike IgG (63,160 ELISA units) and neutralization (3906) responses that exceeded geometric mean responses in convalescent serum from mostly symptomatic COVID-19 patients (8344 and 983, respectively).
- No serious adverse events were noted. Reactogenicity was absent or mild in the majority of participants, more common with adjuvant, and of short duration (mean, ≤2 days).
- NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in COVID-19 convalescent serum.
- The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype.
- NVX-CoV2373 is currently in multiple Phase 2 clinical trials.
- The trial was supported by funding from the Coalition for Epidemic Preparedness Innovations (CEPI).
- After closing with a 2.07% decline at $102.90 in Wednesday's regular session, shares gained 3.79% and topped $106.80 in after-hours trading.
